olivLaw · European equity research
Solvonis Therapeutics PLC SVNS.L
United Kingdom · London Stock Exchange · ISIN GB00BMD1Z199 · Vertical: Listed companies from United Kingdom
Solvonis Therapeutics PLC is a pre-revenue holding company in London focused on intellectual property and the development of therapies for mental health and substance use disorders. Its main asset is a portfolio of intangible assets, while the company depends on external funding to continue development, and the auditor reports a material uncertainty over going concern. For small biotech companies, its case shows how much of the book value depends on the results of a single clinical programme.
At the close of 05 Nov 2026, Solvonis Therapeutics PLC (SVNS.L) stock was 0.00 GBP (+7.53% on the day), with beta 0.45, 52-week range 0.00–0.00 GBP.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 46.1
- neutral
- Bollinger (20, 2)
- 0.00 – 0.00
- in the lower half of the band · %B 0.48 · band width 25.5%
- SMA 50 / 200
- 0.00 / 0.00
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.00 / -0.00
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −2.9% | −0.6% | −2.3 pp | — |
| 3 months | −31.0% | −4.2% | −26.9 pp | — |
| 6 months | −56.5% | +4.3% | −60.9 pp | — |
| Year to date | −67.7% | +7.5% | −75.3 pp | — |
| 1 year | −66.1% | +9.9% | −76.0 pp | +5.8% |
| 3 years | unavailable | +49.8% | unavailable | +26.3% |
| 5 years | unavailable | +42.8% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 587.0 k | 0 | 0 |
| Revenue YoY | unavailable | −100.0% | unavailable |
| Net income | -3.1 m | -1.6 m | -5.7 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -0.00 | -0.00 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | -531.5% | unavailable | unavailable |
| Free cash flow | -1.5 m | -1.1 m | unavailable |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 1.7 m GBP
- Financial debt
- unavailable GBP
- Net debt
- unavailable GBP
- Equity
- 6.2 m GBP
- Total assets
- 7.6 m GBP
- Debt / equity
- unavailable
- Current ratio
- 4.00x
- ROE
- -123.8%
- ROA
- -106.4%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (GBP)
Income statement · GBP
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 587.0 k | 0 | 0 | esef· 27 May 2026verified |
| Cost of revenue | 329.0 k | 0 | — | esef· 07 May 2025verified |
| Gross profit | 258.0 k | 0 | — | esef· 07 May 2025verified |
| Operating income | -3.1 m | -1.4 m | -5.7 m | esef· 27 May 2026verified |
| Depreciation & amortisation | 179.0 k | 0 | — | esef· 07 May 2025verified |
| EBITDA | -2.9 m ≈ | -1.4 m ≈ | — | esef· 07 May 2025derived |
| Interest expense | 3.0 k | 64.0 k | 0 | esef· 27 May 2026verified |
| Pre-tax income | -3.1 m | -1.4 m | -5.7 m | esef· 27 May 2026verified |
| Income tax | 0 | 0 | 0 | esef· 27 May 2026verified |
| Net income | -3.1 m | -1.6 m | -5.7 m | esef· 27 May 2026verified |
| Diluted EPS | — | -0.00 | -0.00 | esef· 27 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · GBP
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 155.0 k | 757.0 k | 1.7 m | esef· 27 May 2026verified |
| Receivables | 108.0 k | 58.0 k | 198.0 k | esef· 27 May 2026verified |
| Inventories | 51.0 k | 0 | — | esef· 07 May 2025verified |
| Current assets | 314.0 k | 815.0 k | 1.9 m | esef· 27 May 2026verified |
| Property, plant & equipment, net | 39.0 k | 0 | — | esef· 07 May 2025verified |
| Intangibles (excl. goodwill) | 2.1 m | 2.1 m | 5.7 m | esef· 27 May 2026verified |
| Total assets | 2.4 m | 3.2 m | 7.6 m | esef· 27 May 2026verified |
| Accounts payable | 249.0 k | 119.0 k | 480.0 k | esef· 27 May 2026verified |
| Current liabilities | 386.0 k | 119.0 k | 480.0 k | esef· 27 May 2026verified |
| Total liabilities | 408.0 k | 119.0 k | 1.4 m | esef· 27 May 2026verified |
| Equity | 2.0 m | 3.1 m | 6.2 m | esef· 27 May 2026verified |
Cash flow · GBP
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -1.2 m | -1.1 m | -3.3 m | esef· 27 May 2026verified |
| Capex | 216.0 k | 0 | — | esef· 07 May 2025verified |
| Free cash flow | -1.5 m ≈ | -1.1 m ≈ | — | esef· 07 May 2025derived |
| Investing cash flow | -232.0 k | -337.0 k | 0 | esef· 27 May 2026verified |
| Financing cash flow | 0 | 2.1 m | 4.2 m | esef· 27 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 1 of at least 6
- score weight coverage: 4.2% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
4% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 1 of at least 6; score weight coverage: 4.2% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 4.0x | 100 (on a fixed band) | 100% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
SOLVONIS THERAPEUTICS PLC (SVNS.L). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 0 GBP in 2025; ROE -123.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 1 of at least 6; score weight coverage: 4.2% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 4.0x
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from United Kingdom · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| BATS.LBritish American Tobacco P.L.C. | 104.3 bn | 13.5 | 16.5% | 30.3% | −1.0% | +7% / +88% |
| ABF.LAssociated British Foods PLC | 14.7 bn | 14.3 | 9.2% | 5.3% | −3.1% | −5% / −15% |
| 0EV1.LCarnival PLC | 5.5 bn | 4.1 | 46.7% | 13.4% | +6.4% | unavailable / unavailable |
| BAB.LBabcock International Group PLC | 5.1 bn | 24.7 | 34.7% | 4.1% | +7.2% | −10% / +158% |
| AUTO.LAutotrader Group PLC | 4.8 bn | 16.4 | 60.2% | 47.1% | +3.9% | −13% / −23% |
| BBY.LBalfour Beatty PLC | 4.2 bn | 16.3 | 23.2% | 2.8% | +15.2% | +20% / +160% |
| ABDN.LAberdeen Group PLC | 4.1 bn | 10.8 | 8.0% | 28.9% | −2.1% | +11% / +41% |
| BKG.LThe Berkeley Group Holdings PLC | 3.6 bn | 11.3 | 8.8% | 13.4% | −4.2% | −0% / −22% |
| BME.LB&M European Value Retail PLC | 2.9 bn | 17.4 | 21.2% | 2.8% | +3.7% | +68% / −51% |
| AJB.LAj Bell PLC | 2.4 bn | 22.8 | 49.9% | 33.1% | +18.0% | +8% / +128% |
| ASHM.LAshmore Group PLC | 1.4 bn | 13.9 | 13.1% | 71.6% | −0.1% | +28% / +18% |
| BCG.LBaltic Classifieds Group PLC | 1.2 bn | 23.2 | 15.8% | 57.6% | +6.9% | −99% / −99% |
| APN.LApplied Nutrition PLC | 763.6 m | 36.2 | 41.2% | 19.7% | +24.2% | +71% / unavailable |
| BAG.LA.G. Barr P.L.C. | 671.9 m | 14.4 | 14.4% | 10.8% | +4.0% | −7% / +26% |
| ASC.LAsos PLC | 494.5 m | — | -81.3% | -12.0% | −14.7% | +71% / +8% |
| ALFA.LAlfa Financial Software Holdings PLC | 486.8 m | 16.3 | 61.5% | 23.8% | +15.3% | −28% / +10% |
| AML.LAston Martin Lagonda Global Holdings PLC | 344.3 m | — | -93.4% | -39.2% | −20.6% | −45% / −85% |
| APTD.LAptitude Software Group PLC | 111.3 m | 28.5 | 7.2% | 6.2% | −7.3% | −30% / −23% |
| AMGO.LAmigo Holdings PLC | 9.9 m | — | — | — | −81.9% | +325% / +844% |
| ASBE.LAssociated British Engineering PLC | 605.3 k | — | -19.1% | — | unavailable | unavailable / unavailable |
| AMIF.LAmicorp Fs (uk) PLC | 221.6 k | 0.1 | 27.5% | 9.1% | +8.1% | unavailable / unavailable |
| AAF.LAirtel Africa PLC | — | — | 24.1% | 10.6% | +29.5% | −7% / +164% |
| AAL.LAnglo American PLC | — | — | -19.3% | -20.2% | +4.5% | +30% / +76% |
| ACG.LAcg Metals Limited | — | — | -80.3% | -32.0% | +134.8% | +60% / +63% |
| AEP.LAnglo-Eastern Plantations PLC | — | — | 16.1% | 19.5% | +25.0% | +5% / +113% |
1- and 3-year price returns: for SVNS.L from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Solvonis Therapeutics PLC is a pre-revenue holding company in London focused on intellectual property and the development of therapies for mental health and substance use disorders. Its main asset is a portfolio of intangible assets, while the company depends on external funding to continue development, and the auditor reports a material uncertainty over going concern. For small biotech companies, its case shows how much of the book value depends on the results of a single clinical programme.
SWOT
Strengths
- The intellectual property portfolio acquired with the Awakn acquisition constitutes the company's main accounting asset 1.
- The board has experience across a range of fields, which could support execution of the strategy.
Weaknesses
Opportunities
- If SVN-001 achieves favourable results, monetisation through partnerships could open new funding sources.
- A differentiated CNS pipeline could strengthen the company's position in psychiatry and addiction.
- High medical need in addiction could support investor and partner interest.
Threats
- Clinical failure or delays in development programmes could reduce the value of intangible assets.
- Difficult capital market conditions could limit the funding needed to continue development.
- Evolving regulatory requirements could impose additional studies and delays.
Risks
- Funding dependencehigh
The company is pre-revenue and depends on external funds; the report provides no assurance that funding will be available on acceptable terms 1.
- Going concern uncertaintyhigh
The auditor flagged a material uncertainty over going concern because future funding is uncertain 1.
- Clinical and development riskhigh
Programmes may fail or be delayed, and safety and efficacy data could prove insufficient 1.
- Intellectual property riskmedium
Patent applications may not proceed to grant or may provide less protection than the company expects 1.
- Integration riskmedium
Integrating the Awakn group and allocating resources across programmes could delay progress 1.
Investment thesis
What would need to be true (bull case)
- If SVN-001 meets its phase III objectives, the value of intangible assets could be reassessed favourably and open partnership options.
- The Awakn acquisition could create a differentiated CNS pipeline that might attract partner interest.
- Large social need in addiction could support long-term monetisation of the programmes.
What would break the thesis
- The company has no revenue, and the auditor flagged going concern uncertainty, which could limit strategic options.
- The book value of intangibles depends on clinical results and could fall if programmes fail or are delayed.
- If funding cannot be obtained on acceptable terms, the company could be forced to slow or narrow its programmes.
What to watch
- SVN-001 phase III progress and clinical data2027
- Outcome of funding raises or partnership discussionsnext 10-K
- Evolution of regulatory requirements for SVN-0022027
- Any further reassessments of intangibles and auditor conclusionsnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The group operates as a holding company, and the annual report shows it has historically had no material income; revenue from continuing operations is zero in fiscal 2025. The stated strategy is developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for these conditions. The main accounting asset is the intangible value, which includes intellectual property acquired with the Awakn Group acquisition 1.
The company is in research and development and depends on raising funds to continue its programmes. The report notes that the group is pre-revenue and that there can be no assurance that future funding will be available on acceptable terms, or at all 1.
The Awakn acquisition brought a portfolio of intellectual property, and the board says it aims to build a clinically relevant and differentiated CNS pipeline focused on addiction and psychiatry. Programme SVN-001 is in phase III, while SVN-002 is being developed through a planned 505(b)(2) strategy 1.
Segments
SVN-001 programme
SVN-001 is the most advanced programme in the portfolio, in phase III, and management has chosen to prioritise completing this phase before reassessing route-to-value options. The auditor found that the value of intellectual property linked to this programme was reduced to fair value less costs to dispose 1.
SVN-002 programme
SVN-002 is being developed through a 505(b)(2) regulatory strategy, and the report indicates that this regulatory path could require additional studies or data before approval 1.
Market context
The company operates in the market for therapies for mental health and substance use disorders, an area with high unmet medical need but also high regulatory and funding requirements. The report does not provide market size data, and the company's book value depends on the clinical results of a small number of programmes 1.
For a company in research and development, access to venture capital and partnerships directly affects its ability to continue programmes, and capital market conditions could change the pace of development 1.
Trends
- Evolving regulationheadwind
Regulatory requirements for psychiatric therapies and addiction treatments may evolve, and authorities could require additional studies before programmes progress 1.
- Interest in addiction treatmentstailwind
Medical need in addiction remains high, and the board believes the social impact of effective therapies could be significant 1.
- Funding conditionsheadwind
Small biotech companies depend on external capital, and tougher market conditions could limit the ability to raise funds 1.
- Consolidation through acquisitionsmixed
Integrating the intellectual property acquired with Awakn could accelerate development of a differentiated pipeline if execution is effective 1.
Competitive position
The annual report does not describe direct competitors. No verified list of competitors can be drawn from the available documents, so the competitive analysis is limited to the general context of psychiatric therapy development.
Competitive positioning depends mainly on the clinical results of SVN-001 and SVN-002 and on the ability to secure partnerships, which the document describes as uncertain 1.
- Not identified in source
The annual report does not name competitors; no names from outside the source are included.
- CNS biotech companies
General category of developers of psychiatric therapies; the source contains no specific verified names.
- Developers of addiction treatments
General category of companies targeting substance use disorders; the source does not identify them.
- Potential licensing partners
The board mentions possible partnerships without naming entities from the source.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202527 May 2026
- Annual report 202407 May 2025
Sources
- [1] Annual report, fiscal year ended 2025-12-31 (ESEF) · SEC / Solvonis Therapeutics PLC · 31 Dec 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.